UAE Antibacterial (Antibiotics) Drugs Market Report 2022 to 2030

UAE Antibacterial (Antibiotics) Drugs Market Analysis

$ 3999

UAE Antibacterial (Antibiotics) Drugs Market is at around $0.25 Bn in 2023 and is projected to reach $0.3 Bn in 2030, exhibiting a CAGR of 5.2% during the forecast period. The market is being driven by the increasing prevalence of infectious diseases, government healthcare initiatives, and growing population and urbanization. The market is dominated by key players like Julphar Gulf Pharmaceutical Industries, Tabuk Pharmaceuticals, Pfizer, AstraZeneca plc, GlaxoSmithKline (GSK), Johnson & Johnson Inc. (J&J), Merck & Co., Sanofi, Novartis, and F. Hoffmann-La Roche Ltd.

ID: IN10AEPH005 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Aneri Parekh

Buy Now

UAE Antibacterial (Antibiotics) Drugs Market Executive Summary

UAE Antibacterial (Antibiotics) Drugs Market is at around $0.25 Bn in 2023 and is projected to reach $0.3 Bn in 2030, exhibiting a CAGR of 5.2% during the forecast period.

The Antibiotics Market in the United Arab Emirates provides a range of antibiotic classes, such as cephalosporins, fluoroquinolones, and penicillin, to meet the medical demands of healthcare facilities, including clinics, hospitals, and retail pharmacies. The dynamics of this market in the United Arab Emirates are shaped by the growing prevalence of infectious diseases, expanding healthcare infrastructure, and government programs for improved healthcare access.

The increased incidence of infectious diseases and the expansion of healthcare infrastructure are driving the continuous rise of the UAE antibiotics market. Government programs that increase healthcare awareness and access fuel market growth even further. Important players are taking advantage of technological developments to create novel antibiotics, improve the effectiveness of treatment, and satisfy changing patient needs.

Over the past few years, there have been major changes in the antibiotic market. The market was estimated at $50.91 Bn in 2023 and is expected to keep expanding. The development of novel products and the rising incidence of infectious diseases are driving this expansion. These advancements can be attributed to the rising need for novel antimicrobial formulations, increased efforts in research and development, and an increase in the prescription of antibiotics. The introduction of advanced antibiotics and the growing urbanization of the population have an impact on the market's growth.

With a significant market share in several antibiotics such as macrolides, cephalosporins, and penicillin, Julphar is a market leader in the United Arab Emirates. Many of Julphar's antibiotics are produced in the UAE at its state-of-the-art facilities, ensuring a steady supply and assisting in the nation's pharmaceutical self-sufficiency. Julphar's revenue in the first half of 2023 was $232 Mn which showed growth in the UAE market.

UAE antibacterial (antibiotics) drugs market

Market Dynamics

Market Growth Drivers:

Growing Population and Urbanization: Over the past few decades, the UAE has seen rapid population expansion and urbanization, which has increased the demand for healthcare services, particularly antibiotics. The population of the UAE was 9.97 Mn in 2023.

Government Healthcare Initiatives: To ensure that the population and residents have access to high-quality healthcare, the UAE government has made large investments in healthcare services and infrastructure. Government programs to upgrade medical facilities and expand accessibility to necessary medications, such as antibiotics, propel market expansion.

Increasing Prevalence of Infectious Diseases: International travel, migration, and changing lifestyles keep infectious diseases a concern in the UAE despite improvements in healthcare infrastructure and sanitation. This increases the antibiotic need for diseases caused by bacteria.

Market Restraints:

Alternative Therapies: As interest in alternative therapies like probiotics, herbal medicines, and immune-boosting supplements grows, there may be less need for antibiotics, which would restrict market growth.

Economic Factors: Changes in the economy and budgetary constraints may have an effect on healthcare spending and result in financial restrictions for the purchase and use of antibiotics.

Increased Preventive Medicine: Vaccination and preventive medicine programs may minimize infections and antibiotic use.

Healthcare Policies and Regulatory Landscape

The Ministry of Health and Prevention (MoHAP) of the United Arab Emirates (UAE) is in charge of overseeing pharmaceutical regulations. The process involves submitting a request online through the MoHAP website, meeting all prerequisites, covering all associated expenses, and forwarding the report to the ministerial committee. To get a drug approved, compliance with Good Manufacturing Practices (GMP) is essential. Adherence to stringent quality standards is crucial for pharmaceutical manufacturing facilities to ensure product consistency and quality, thereby complicating the process.

Competitive Landscape

Key Players:

Julphar Gulf Pharmaceutical Industries
Tabuk Pharmaceuticals
Pfizer
AstraZeneca plc
GlaxoSmithKline (GSK)
Johnson & Johnson Inc. (J&J)
Merck & Co.
Sanofi
Novartis
F. Hoffmann-La Roche Ltd

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UAE Antibacterial (Antibiotics) Drugs Market Segmentation

By Drug Class

Cephalosporins
Penicillin
Fluoroquinolone
Macrolides
Carbapenems
Aminoglycosides
Sulfonamides
7-ACA
Others

By Type

Branded Antibiotics
Generic Antibiotics

By Action Mechanism

Cell Wall Synthesis Inhibitors
Protein Synthesis Inhibitors
DNA Synthesis Inhibitors
RNA Synthesis Inhibitors
Mycolic Acid Inhibitors
Others

By Spectrum

Broad-spectrum Antibiotic
Narrow-spectrum Antibiotic

By Administration

Oral
Intravenous
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.